Anti Type Vii Collagen Antibody C5539880
Antibody causing a blistering skin condition where the body attacks its own collagen. Managed with immunosuppressants and wound care.
Key facts at a glance
- ICD-10
- L98.9
- ICD-11
- EA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Immunosuppressive therapy
Corticosteroids and other immunosuppressants help control the autoimmune blistering process in epidermolysis bullosa acquisita by reducing antibody-mediated inflammation.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Advanced wound care management
Specialized wound care techniques including gentle cleansing, non-adherent dressings, and appropriate topical treatments promote healing and prevent secondary infections.
Additional treatment options
Colchicine therapy
Colchicine may be used as a steroid-sparing agent in epidermolysis bullosa acquisita to reduce blister formation and inflammation.
medicationTrauma prevention measures
Implementing protective measures to minimize mechanical trauma to skin, including padding, soft clothing, and avoiding activities that cause skin friction or injury.
lifestyleDapsone therapy
Dapsone has anti-inflammatory properties and may be used as an alternative or adjunctive therapy for controlling blistering in epidermolysis bullosa acquisita.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Type Vii Collagen Antibody C5539880?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kasperkiewicz M, Schmidt E, Zillikens D. European guidelines for management of epidermolysis bullosa acquisita. Br J Dermatol. 2022.
Bhoomi P, Hammers CM, Stanley JR. Anti-type VII collagen autoantibodies: pathogenesis and clinical manifestations. J Invest Dermatol. 2021.
Fritz TJ, Bayerl C, Worm M. Randomized controlled trial of colchicine versus dapsone for epidermolysis bullosa acquisita. J Eur Acad Dermatol. 2020.
Vorobyev A, Ludwig RJ, Recke A. Diagnosis of anti-type VII collagen autoimmune disease. Clin Immunol. 2019.
Medication Comparisons
Compare medications used to treat Anti Type Vii Collagen Antibody C5539880. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy